Latent Labs Launches LatentX

Latent Labs Launches LatentX

22 July 2025

Latent Labs has launched LatentX, a web-based AI model for protein design, six months after securing $50 million in funding. The model aims to democratise access to advanced protein engineering for researchers and pharmaceutical companies.

LatentX has demonstrated state-of-the-art performance in lab tests, with high viability rates in designed proteins. Unlike AlphaFold's structure prediction, LatentX generates novel biological entities, potentially accelerating drug discovery and reducing costs for previously untreatable conditions. The company's licensing model prioritises accessibility, offering free access while planning paid advanced features to sustain innovation.

Latent Labs' commitment to accessibility is a key aspect of its approach, offering a web-based model that can be accessed by a wide range of users. This empowers both academic researchers and large pharmaceutical companies to design novel proteins directly from their web browsers.

AI generated content may differ from the original.

Published on 22 July 2025
aiproteindesigndrugdiscoverybiotechlatentx
  • AI Repurposes Diabetes Drug

    AI Repurposes Diabetes Drug

    Read more about AI Repurposes Diabetes Drug
  • Biological Computer Lab-Grown Neurons

    Biological Computer Lab-Grown Neurons

    Read more about Biological Computer Lab-Grown Neurons
  • Insilico's AI cancer drug trial

    Insilico's AI cancer drug trial

    Read more about Insilico's AI cancer drug trial
  • AI 'Hallucinations' Remain Problematic

    AI 'Hallucinations' Remain Problematic

    Read more about AI 'Hallucinations' Remain Problematic
Latent Labs Launches LatentX